at home ketamine
Spotlight: Ketamine Harm Reduction
Prevention & Treatment in Ketamine Use Disorder - When a medicine becomes a poison
ketamine research
oxycodone withdrawal
Spotlight: The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal (Lehane, et al, 2025)
"These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. "
ketamine
Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
ketamine
Spotlight: Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study (Beaglehole, et al, 2025)
"We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."
iv ketamine
Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)
" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "
ketamine
Spotlight: Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review (Silva, et al, 2025)
"Our findings indicate that ketamine reduces excitotoxicity and inflammation, which may contribute to neuroprotection in acute neurological injuries. These insights underscore ketamine's potential as an adjunctive neuroprotective agent, warranting further clinical investigation...
iv ketamine
Spotlight: First study to compare two ketamine therapies for patients with severe depression
IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato)
ketamine
Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders (Havlik, et al, 2025)
"The most frequently studied substances were psilocybin (n=64; 35.4%) and ketamine (n=61; 33.7%). Trials were notably concentrated within a small number of leading academic institutions."
ketamine
Evaluating oral ketamine's adverse side effects in chronic pain patients (Hom, et al, 2025)
Evaluating oral ketamine’s adverse side effects in chronic pain patients - PubMedOur results suggest that at daily doses above
ketamine
Spotlight: Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review (Meisner, et al, 2025)
"In this naturalistic sample of patients with similarly severe TRD treated in a ketamine subspecialty service over a 4–5-week induction period, treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine."
ketamine
Spotlight: Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review (Thomas, et al, 2025)
"...ketamine has been tested in nine RBCTs targeting cocaine, alcohol, opioid use disorder, and nicotine, suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences."
ketamine
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)
"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
ketamine
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)
"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
ketamine
Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)
"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
ketamine
Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)
"...participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group. "
ketamine
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study (Patarroyo-Rodriguez, et al, 2025)
La ketamina reduce la utilización del departamento de emergencias asociada a la suicidabilidad en pacientes con depresión resistente al tratamiento: un estudio de imagen especular de 6 meses
ketamine
Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)
Factor de crecimiento endotelial vascular: un factor clave en la aparición y tratamiento de la depresión
ketamine
Spotlight: Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review (Kew, et al, 2023)
"...Outcomes were largely positive for the addition of psychotherapy to ketamine treatment...The combination of psychotherapy and ketamine offers promise for the treatment of psychiatric disorders"